Moleculin Biotech (MBRX) shares dropped about 19% in recent Wednesday trading after the company said no patients achieved complete response in the phase 1b/2 study of Annamycin for the treatment of soft tissue sarcoma lung metastases, a type of cancer.
The trial, however, demonstrated a clinical benefit rate of 59.4%, primarily comprising 18 cases of stable disease and one partial response, the company said.
The median progression-free survival in the 36 subjects participating in the trial was 63 days, while median overall survival clocked in at 411 days, the company said.
In the phase 2 portion of the study, which was made up of 17 subjects, the median progression-free survival was 105 days, with overall survival coming in at 13.5 months, the company added.
Annamycin holds the US Food and Drug Administration's orphan drug designation for the treatment of soft tissue sarcoma.
Price: 0.68, Change: -0.16, Percent Change: -18.55
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。